Compound index

Growth Hormone Secretagogues & GHRH Analogs

Sermorelin

Late-stage human trialsHistorical FDA approvals withdrawn

Last reviewed: 2026-11-19

Evidence status & limitations

Geref was historically approved for specific pediatric and diagnostic uses. Its approvals were withdrawn in 2009; this is distinct from the later finding that withdrawal from sale was not for safety or effectiveness reasons.

Regulatory status

Geref approvals were withdrawn effective June 18, 2009. Historical approval is not current approval; withdrawal of approval is separate from FDA’s later determination about reasons for withdrawal from sale.

    Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

    WADA prohibited status: current list and context

    Known risks & open questions

    Flushing, headache and hypersensitivity were reported; approval does not establish unrelated adult wellness uses.

    Key sources

    Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.

    Related compounds

    • CJC-1295

      Same target family · A 29-amino-acid chain. · Early human trials

    • Examorelin

      Same scientific class · A 6-amino-acid chain. · Early human trials

    • Ipamorelin

      Same scientific class · A 5-amino-acid chain. · Early human trials

    • Modified GRF (1–29)

      Same target family · A 29-amino-acid chain. · Cell/lab studies only

    • Pralmorelin

      Same scientific class · A 6-amino-acid chain. · Early human trials

    Related glossary terms